THE APEX TIMES
The Louisiana appellate court upheld a jury award after finding that talc in Johnson & Johnson’s baby powder contributed to a New Orleans woman’s mesothelioma, according to a report carried by Yahoo Finance.
A Louisiana appeals court has upheld a multimillion-dollar damages award in a mesothelioma case that plaintiffs alleged was caused by exposure to talc in Johnson & Johnson’s baby powder, a report published Monday said.
The case centered on claims that talc products, when used over time, contributed to the development of mesothelioma, a cancer linked to asbestos exposure. In the trial, a jury concluded that Johnson & Johnson’s talc-based baby powder caused the plaintiff’s illness, the report said.
On appeal, the court affirmed the jury’s finding and left the verdict in place, according to the Yahoo Finance account of the ruling. The report did not provide granular details on the appeals court’s legal reasoning, such as whether it addressed causation, product-defect arguments, or evidentiary issues in depth.
Johnson & Johnson has faced a large number of lawsuits related to talc and cancer allegations over multiple years. In this latest dispute, the appellate decision means the plaintiff’s award survives the first major round of appellate review, at least for now, and it adds to the growing body of litigation outcomes that have varied across courts and jurisdictions.
Talc is widely used in consumer products, including baby powder, for moisture control. The litigation hinges on whether talc in specific products is contaminated with asbestos or whether the product otherwise contributed to cancer risk. Plaintiffs typically argue that long-term exposure can lead to serious disease, while defendants have argued for decades that their products do not contain asbestos and that evidence does not support a causal link.
The Yahoo Finance report framed the verdict as “multimillion,” but it did not specify the exact dollar amount or the breakdown of the award in the brief description available here. It also did not state whether the defendant sought a further appeal, whether Johnson & Johnson plans to challenge the decision through additional appellate steps, or whether any settlement discussions were ongoing.
From a business perspective, outcomes like this matter less for any single company line item in the short term than for the broader litigation and risk profile around talc-containing products. Each appeals decision can influence how courts evaluate evidence, how juries hear similar claims, and how both plaintiffs and defendants assess the likelihood of trial risk.
What is still not clear from the available report is what the appeals court relied on most heavily, whether the court addressed expert testimony in particular, and whether the decision turned on procedural issues or substantive findings. The case also leaves open questions about how Johnson & Johnson intends to respond and whether future rulings will trend toward affirming or revising damages awards in similar claims.
The beverage alcohol maker said an executive will discuss company developments at the 2026 gathering of consumer and retail investors.
The alternative asset manager said its president and chief operating officer is scheduled to present at the Goldman Sachs event on Wednesday, according to a new announcement filed through market channels.
UnitedHealth slid after the Centers for Medicare and Medicaid Services proposed expanding Medicare Advantage audits and potentially recovering plan overpayments dating back to 2018, a move other managed-care and pharmacy-linked insurers also faced.
The tech investor argues that regulatory or compliance pressure may force NVIDIA’s latest GPUs to include buyer verification checks that amount to a biometric-style “kill switch,” aiming to deter resale or diversion to restricted end users.
A recent market note argues that Alphabet’s platform could offer better five-year stock upside than Amazon, pointing to how AI is being embedded into cloud products and distribution. The piece stops short of providing new, primary data on near-term earnings.
Ahead of its late-Tuesday results, Nvidia is set to update investors on performance for its fiscal third quarter, a key checkpoint for demand trends in AI-linked data center spending.
In results for its third quarter of fiscal 2027, NVIDIA said revenue rose more than twofold year over year, with data center revenue accounting for nearly all of the company’s growth.
Broad-market indexes slipped on Tuesday, with Nvidia’s upcoming earnings acting as a key weight on sentiment, according to Yahoo Finance.
A new Yahoo Finance comparison frames Eaton’s electrical exposure as a lever for data-center growth, while casting Honeywell’s strategy shift toward automation as a tradeoff that could change how investors view risk in 2027.
In a Q3 2026 earnings call posted by Yahoo Finance, Home Depot highlighted a CEO handoff and lowered growth expectations tied to its SRS metric, indicating a more cautious near-term view of demand.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...